Effectiveness of a hospital-based vascular screening programme (SMART) for risk factor management in patients with established vascular disease or type 2 diabetes: A parallel-group comparative study

Journal of Internal Medicine

Volumn 268, Issue 1, 2010, Pages 83-93

  Brouwer, B G ^a   Visseren, F L J ^a   Algra, A ^a,b   Van Bockel, J H ^b   Bollen, E L E M ^b   Doevendans, P A ^a   Greving, J P ^a   Kappelle, L J ^a   Moll, F L ^a   Pijl, H ^b   Romijn, J A ^b   Van Der Wall, E E ^b   Van Der Graaf, Y ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Atherosclerosis; Cardiovascular risk; Risk factors; Secondary prevention; Type 2 diabetes; Vascular disease

Indexed keywords

LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; AGED; ANGINA PECTORIS; ARTERY DISEASE; ARTICLE; CEREBROVASCULAR DISEASE; COMPARATIVE STUDY; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DIABETIC PATIENT; DIASTOLIC BLOOD PRESSURE; EVIDENCE BASED MEDICINE; FEMALE; HEALTH PROGRAM; HEART INFARCTION; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; RISK FACTOR; RISK MANAGEMENT; SCREENING; SYSTOLIC BLOOD PRESSURE; VASCULAR DISEASE;

ADULT; AGED; AGED, 80 AND OVER; ATHEROSCLEROSIS; BLOOD PRESSURE; CHOLESTEROL; CHOLESTEROL, LDL; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; FEMALE; HOSPITALS, UNIVERSITY; HUMANS; MALE; MASS SCREENING; MIDDLE AGED; RISK FACTORS; YOUNG ADULT;

EID: 77953521588     PISSN: 09546820     EISSN: 13652796     Source Type: Journal    
DOI: 10.1111/j.1365-2796.2010.02229.x     Document Type: Article

References (38)

1. Kannel WB. Overview of atherosclerosis. Clin Ther 1998 20 (Suppl. B B2 17.
2. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002 324 : 71 86.
3. Cholesterol Treatment Trialists' Collaborators. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005 366 : 1267 1278.
4. The Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000 342 : 145 153.
5. EUROASPIRE I and II Group. Clinical reality of coronary prevention guidelines: a comparison of EUROASPIRE I and II in nine countries. European Action on Secondary Prevention by Intervention to Reduce Events. Lancet 2001 357 : 995 1001.
6. EUROSPIRE II Study group. Lifestyle and risk factor management and use of drug therapies in coronary patients from 15 countries; principal results from EUROASPIRE II Euro Heart Survey Programme. Eur Heart J 2001 22 : 554 572.
7. Cheng EM, Asch SM, Brook RH et al. Suboptimal control of atherosclerotic disease risk factors after cardiac and cerebrovascular procedures. Stroke 2007 38 : 929 934.
8. Graham I, Atar D, Borch-Johnsen K et al. European guidelines on cardiovascular disease prevention in clinical practice: executive summary. Eur Heart J 2007 28 : 2375 2414.
9. Kotseva K, Stagmo M, De Bacquer D, De Backer G, Wood D. Treatment potential for cholesterol management in patients with coronary heart disease in 15 European countries: findings from the EUROASPIRE II survey. Atherosclerosis 2008 197 : 710 717.
10. Kotseva K, Wood D, De Backer G, De Bacquer D, Pyorala K, Keil U. Cardiovascular prevention guidelines in daily practice: a comparison of EUROASPIRE I, II, and III surveys in eight European countries. Lancet 2009 373 : 929 940.
11. De Backer G, Ambrosioni E, Borch-Johnsen K et al. European guidelines on cardiovascular disease prevention in clinical practice. Third Joint Task Force of European and Other Societies on Cardiovascular Disease Prevention in Clinical Practice. Eur Heart J 2003 24 : 1601 1610.
12. Dutch Institute for Healthcare Improvement CBO and Dutch College of General Practitioners. Dutch guideline on cardiovascular risk management, 2006.
13. O'Brien E, Bouchier-Hayes D, Fitzgerald D, Atkins N. The arterial organ in cardiovascular disease: ADAPT (arterial disease assessment, prevention, and treatment) clinic. Lancet 1998 352 : 1700 1702.
14. Campbell NC, Ritchie LD, Thain J, Deans HG, Rawles JM, Squair JL. Secondary prevention in coronary heart disease: a randomised trial of nurse led clinics in primary care. Heart 1998 80 : 447 452. (Pubitemid 28535530)
15. Ferguson T. Digital doctoring - opportunities and challenges in electronic patient-physician communication. JAMA 1998 280 : 1361 1362.
16. McHugh F, Lindsay GM, Hanlon P et al. Nurse led shared care for patients on the waiting list for coronary artery bypass surgery: a randomised controlled trial. Heart 2001 86 : 317 323.
17. Quist-Paulsen P, Gallefoss F. Randomised controlled trial of smoking cessation intervention after admission for coronary heart disease. BMJ 2003 327 : 1254 1257.
18. Gaede P, Vedel P, Larsen N, Jensen GV, Parving HH, Pedersen O. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 2003 348 : 383 393. (Pubitemid 36159355)
19. Wood DA, Kotseva K, Connolly S et al. Nurse-coordinated multidisciplinary, family-based cardiovascular disease prevention programme (EUROACTION) for patients with coronary heart disease and asymptomatic individuals at high risk of cardiovascular disease: a paired, cluster-randomised controlled trial. Lancet 2008 371 : 1999 2012.
20. Rehring TF, Sandhoff BG, Stolcpart RS, Merenich JA, Hollis HW Jr. Atherosclerotic risk factor control in patients with peripheral arterial disease. J Vasc Surg 2005 41 : 816 822.
21. Simons PC, Algra A, van de Laak MF, Grobbee DE, van der Graaf Y. Second manifestations of ARTerial disease (SMART) study: rationale and design. Eur J Epidemiol 1999 15 : 773 781.
22. Wilson JT, Hareendran A, Grant M et al. Improving the assessment of outcomes in stroke: use of a structured interview to assign grades on the modified Rankin Scale. Stroke 2002 33 : 2243 2246.
23. Pentecost MJ, Criqui MH, Dorros G et al. Guidelines for peripheral percutaneous transluminal angioplasty of the abdominal aorta and lower extremity vessels. A statement for health professionals from a special writing group of the Councils on Cardiovascular Radiology, Arteriosclerosis, Cardio-Thoracic and Vascular Surgery, Clinical Cardiology, and Epidemiology and Prevention, the American Heart Association. Circulation 1994 89 : 511 531.
24. Rodgers A, MacMahon S, Gamble G, Slattery J, Sandercock P, Warlow C. Blood pressure and risk of stroke in patients with cerebrovascular disease. The United Kingdom Transient Ischaemic Attack Collaborative Group. BMJ 1996 313 : 147.
25. Rashid P, Leonardi-Bee J, Bath P. Blood pressure reduction and secondary prevention of stroke and other vascular events: a systematic review. Stroke 2003 34 : 2741 2748.
26. Lewington S, Clarke R, Qizilbash N, Peto R, Collins R. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002 360 : 1903 1913.
27. Erhardt LR. Barriers to effective implementation of guideline recommendations. Am J Med 2005 118 (Suppl. 12A 36 41.
28. Cushman WC, Ford CE, Cutler JA et al. Success and predictors of blood pressure control in diverse North American settings: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). J Clin Hypertens (Greenwich) 2002 4 : 393 404.
29. Black HR, Elliott WJ, Neaton JD et al. Baseline Characteristics and Early Blood Pressure Control in the CONVINCE Trial. Hypertension 2001 37 : 12 18.
30. Mancia G, De BG, Dominiczak A et al. 2007 ESH-ESC Practice Guidelines for the Management of Arterial Hypertension: ESH-ESC Task Force on the Management of Arterial Hypertension. J Hypertens 2007 25 : 1751 1762.
31. Schuster H. Improving lipid management - to titrate, combine or switch. Int J Clin Pract 2004 58 : 689 694.
32. Kulkarni SP, Alexander KP, Lytle B, Heiss G, Peterson ED. Long-term adherence with cardiovascular drug regimens. Am Heart J 2006 151 : 185 191.
33. Claxton AJ, Cramer J, Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clin Ther 2001 23 : 1296 1310.
34. Goessens BM, Visseren FL, Sol BG, de Man-van Ginkel JM, van der Graaf Y. A randomized, controlled trial for risk factor reduction in patients with symptomatic vascular disease: the multidisciplinary Vascular Prevention by Nurses Study (VENUS). Eur J Cardiovasc Prev Rehabil 2006 13 : 996 1003.
35. McMahon GT, Gomes HE, Hickson HS, Hu TM, Levine BA, Conlin PR. Web-based care management in patients with poorly controlled diabetes. Diabetes Care 2005 28 : 1624 1629.
36. Southard BH, Southard DR, Nuckolls J. Clinical trial of an Internet-based case management system for secondary prevention of heart disease. J Cardiopulm Rehabil 2003 23 : 341 348.
37. Hobbs FD, Erhardt L. Acceptance of guideline recommendations and perceived implementation of coronary heart disease prevention among primary care physicians in five European countries: the Reassessing European Attitudes about Cardiovascular Treatment (REACT) survey. Fam Pract 2002 19 : 596 604.
38. Klungel OH, de BA, Paes AH, Herings RM, Seidell JC, Bakker A. Influence of question structure on the recall of self-reported drug use. J Clin Epidemiol 2000 53 : 273 277.